Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Assets Average (2022 - 2026)

Zentalis Pharmaceuticals has reported Assets Average over the past 5 years, most recently at $271.0 million for Q1 2026.

  • For Q1 2026, Assets Average fell 33.44% year-over-year to $271.0 million; the TTM value through Mar 2026 reached $271.0 million, down 33.44%, while the annual FY2025 figure was $359.7 million, 26.75% down from the prior year.
  • Assets Average for Q1 2026 was $271.0 million at Zentalis Pharmaceuticals, down from $308.1 million in the prior quarter.
  • Over five years, Assets Average peaked at $603.6 million in Q3 2023 and troughed at $271.0 million in Q1 2026.
  • A 5-year average of $466.2 million and a median of $486.8 million in 2022 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: rose 19.59% in 2023 and later crashed 33.44% in 2026.
  • Year by year, Assets Average stood at $534.3 million in 2022, then grew by 6.45% to $568.7 million in 2023, then decreased by 22.54% to $440.5 million in 2024, then tumbled by 30.05% to $308.1 million in 2025, then dropped by 12.04% to $271.0 million in 2026.
  • Business Quant data shows Assets Average for ZNTL at $271.0 million in Q1 2026, $308.1 million in Q4 2025, and $339.5 million in Q3 2025.